Some studies of feprazone.
Feprazone, 200 mg t.d.s., was compared with indomethacin, 25 mg t.d.s. rising to 50 mg t.d.s., in an eight-week double-blind cross-over study in twenty-three patients with active rheumatoid arthritis. Both therapies proved equally efficacious and acceptable. Measurement of the plasma levels of the two drugs showed no consistent correlation between efficacy and plasma concentrations.
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D011298:Feprazone / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011298:Feprazone; D010653:Phenylbutazone; D007213:Indomethacin